Supplemental Cash Flow Information

9 Months Ended

Sep. 30, 2020

Supplemental Cash Flow Information [Abstract]

Supplemental Cash Flow Information

11. Supplemental Cash Flow Information

The following table summarizes supplemental cash flows for the six months ended September 30, 2020 and 2019:

	2020		2019
Cash paid for interest	$	101,000	$	128,000
Non-cash investing and financing activities:
Impact of adoption of lease accounting standards	$	-	$	1,616,000
Gain from change in fair value of interest rate swap derivatives	$	-	$	7,000
Common stock issued upon conversion of convertible note	$	-	$	500,000
Equity issued to purchase intangible assets	$	-	$	145,000
Common  Shares issued for marketing services	$	210,000	$	-
Common  Shares issued for Impact BioMedical	$	3,132,000	$	-
Series A Preferred Shares issued for Impact BioMedical	$	35,187,000	$	-
Long-lived assets acquired through settlement of notes receivable	$	838,000	$	-